Marinus Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de Marinus Pharmaceuticals' es Scott Braunstein , nombrado en Aug 2019, tiene una permanencia de 4.67 años. compensación anual total es $3.21M, compuesta por 20.2% salario y 79.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.2% de las acciones de la empresa, por valor de $152.40K. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 4 años, respectivamente.
Información clave
Scott Braunstein
Chief Executive Officer (CEO)
US$3.2m
Compensación total
| Porcentaje del salario del CEO | 20.2% |
| Permanencia del CEO | 4.9yrs |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 3.7yrs |
| Promedio de permanencia en la Junta Directiva | 4.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$8.00 Price Target
May 11
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Might Not Be As Mispriced As It Looks After Plunging 86%
Apr 16Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 08Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Dec 22Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?
Nov 04Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$145m |
| Dec 31 2023 | US$3m | US$650k | -US$141m |
| Sep 30 2023 | n/a | n/a | -US$134m |
| Jun 30 2023 | n/a | n/a | -US$28m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | US$3m | US$591k | -US$20m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$105m |
| Mar 31 2022 | n/a | n/a | -US$91m |
| Dec 31 2021 | US$4m | US$574k | -US$99m |
| Sep 30 2021 | n/a | n/a | -US$88m |
| Jun 30 2021 | n/a | n/a | -US$84m |
| Mar 31 2021 | n/a | n/a | -US$76m |
| Dec 31 2020 | US$4m | US$556k | -US$76m |
| Sep 30 2020 | n/a | n/a | -US$74m |
| Jun 30 2020 | n/a | n/a | -US$72m |
| Mar 31 2020 | n/a | n/a | -US$69m |
| Dec 31 2019 | US$2m | US$305k | -US$54m |
| Sep 30 2019 | n/a | n/a | -US$49m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$43m |
| Dec 31 2018 | US$210k | n/a | -US$37m |
Compensación vs. Mercado: La compensación total de Scott($USD3.21M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).
Compensación vs. Ingresos: La compensación de Scott ha aumentado mientras la empresa no es rentable.
CEO
Scott Braunstein (61 yo)
4.9yrs
Permanencia
US$3,214,100
Compensación
Dr. Scott N. Braunstein, M.D., has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He serves as an Independent Director at Caribou Biosciences, Inc. since June 2021. He...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Chairman | 4.9yrs | US$3.21m | 0.20% $ 125.6k | |
| COO, CFO & Treasurer | 3.3yrs | US$1.44m | 0.023% $ 14.9k | |
| Chief Medical Officer | 4.8yrs | US$1.37m | 0.023% $ 14.5k | |
| Chief Scientific Officer | no data | sin datos | sin datos | |
| Senior VP of Investor Relations | 1.1yrs | sin datos | sin datos | |
| Senior VP | 4.1yrs | sin datos | 0.016% $ 10.1k | |
| Director of Corporate Communications & Investor Relations | 1.1yrs | sin datos | sin datos | |
| Chief Regulatory & Quality Assurance Officer | no data | sin datos | sin datos | |
| Chief Commercial Officer | 3.7yrs | sin datos | 0.028% $ 18.0k | |
| Senior Vice President of Chemistry | no data | sin datos | sin datos | |
| Senior Vice President of Development | no data | sin datos | sin datos | |
| Senior Vice President of Biometrics | no data | sin datos | sin datos |
3.7yrs
Permanencia media
61yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MRNS se considera experimentado (3.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Chairman | 5.8yrs | US$3.21m | 0.20% $ 125.6k | |
| Lead Independent Director | 15.6yrs | US$202.52k | 0.032% $ 20.4k | |
| Independent Director | 4.6yrs | US$162.52k | 0.010% $ 6.5k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 7.8yrs | US$160.02k | 0.011% $ 7.1k | |
| Independent Director | 3.3yrs | US$154.74k | 0.012% $ 7.4k | |
| Independent Director | 4yrs | US$157.52k | 0.0096% $ 6.2k | |
| Independent Director | 1.5yrs | US$249.21k | sin datos | |
| Independent Director | 1.3yrs | US$304.81k | 0.0044% $ 2.8k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
4.3yrs
Permanencia media
61.5yo
Promedio de edad
Junta con experiencia: La junta directiva de MRNS se considera experimentada (4 años de antigüedad promedio).